MedTrace Logo

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

NCT02016261 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-07-21

No results posted yet for this study

Summary

Open label, non-comparative, prospective study to evaluate cognitive functioning in remitted depression outpatients during long-term preventive treatment with Fluvoxamine (Fevarin®)

Conditions

  • Recurrent Depressive Disorder

Interventions

DRUG

Fluvoxamine

The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Moscow Research Institute of Psychiatry

    lead OTHER

Principal Investigators

  • Alexey E. Bobrov, Professor · Moscow Research Institution of Psychiatry

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016261 on ClinicalTrials.gov